Zydus Life arm Zydus Lifesciences Global FZE inks licensing and supply deal with MSN for tablets used to treat advanced kidney cancer

The deal inked an exclusive licensing and supply agreement with MSN Laboratories for the US market to supply Cabozantinib tablets, which treat advanced kidney cancer.

MSN Lab will be in charge of manufacturing and supplying the generic version of the CABOMETYX drug.

Company Details

Zydus Lifesciences Global FZE will distribute and sell the product in the US market

The total addressable opportunity of Cabozantinib tablets in the US is approximately $1,464 million, as per IQVIA MAT Mar 2024.

Open Demat A/C